An extensive portfolio of vaccines and constantly rising demand have rendered the vaccine contract manufacturing market to be highly competitive with a vast presence of key players across geographies. Along with the safety and effectiveness of vaccines, flooding the market with one’s product clutches equal importance. In order to cater to the rising demand for vaccines and maintain uniform quality, leading industrial players tend to outsource the manufacturing of vaccines to third parties to expedite market entry.
Rising awareness of immunization across geographies contributes to the overall market growth of vaccine contract manufacturing. Additionally, government initiatives enforcing immunization globally have led to rising vaccine demand. The Global Vaccine Action Plan (GVAP) by the World Health Organization (WHO) is an initiative to prevent deaths by expanding access to vaccines by 2020. As of May 2017, Health ministries across 194 countries endorsed a new initiative on strengthening immunization to meet the goals of GVAP. As per the WHO, around 19.5 million infants worldwide were still not provided with the necessary vaccines. With the ever-rising need for vaccines, and with established players primarily focusing on the development of other molecules, outsourcing is mostly the preferred choice. Additionally, in developing nations, the lack of suitable manufacturing setup and skilled labor compels them to engage with contract manufacturers in order to cater to market standards.
Vaccine contract manufacturers comply with the Good Manufacturing Practices and provide concerned quality assurance review documents. With newer advancements in vaccine production, the contract vendors constantly upgrade their production facilities providing up-to-date services. With the initial development process taking place by industrial leaders, third parties are approached for scaling up processes.
Continuous partnerships and acquisitions further catalyze the overall market growth. In October 2017, DCPrime BV a firm developing dendritic cell vaccines for cancer therapy collaborated with apceth Biopharma GmbH contract manufacturer. The collaboration comprises clinical batch production and the development of an expanded-scale manufacturing process for cancer vaccines. However, a few large pharmaceutical firms prefer to maintain vaccine manufacturing in-house to avoid risks of management contingencies and deviation in safety and efficacy. This factor could have a negative impact on the global adoption of contract-based services during the forecast period.
Rising demand for expedited entry of vaccines into the market has rendered the vaccine contract manufacturing market to be highly competitive with a vast outreach across geographies. The key industrial players enjoying a dominant position in this market are Ajinomoto Althea, Inc., Albany Molecular Research, Inc., Cobra Biologics & Pharmaceutical Services, Cytovance Biologics; Catalent, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON plc., IDT Biologika GmbH, Lonza Group, Ltd., Merck KGaA, Paragon Bioservices, Inc., PRA Health Sciences and Others notable players.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends, and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
Rising awareness of immunization across geographies contributes to the overall market growth of vaccine contract manufacturing. Additionally, government initiatives enforcing immunization globally have led to rising vaccine demand. The Global Vaccine Action Plan (GVAP) by the World Health Organization (WHO) is an initiative to prevent deaths by expanding access to vaccines by 2020. As of May 2017, Health ministries across 194 countries endorsed a new initiative on strengthening immunization to meet the goals of GVAP. As per the WHO, around 19.5 million infants worldwide were still not provided with the necessary vaccines. With the ever-rising need for vaccines, and with established players primarily focusing on the development of other molecules, outsourcing is mostly the preferred choice. Additionally, in developing nations, the lack of suitable manufacturing setup and skilled labor compels them to engage with contract manufacturers in order to cater to market standards.
Vaccine contract manufacturers comply with the Good Manufacturing Practices and provide concerned quality assurance review documents. With newer advancements in vaccine production, the contract vendors constantly upgrade their production facilities providing up-to-date services. With the initial development process taking place by industrial leaders, third parties are approached for scaling up processes.
Continuous partnerships and acquisitions further catalyze the overall market growth. In October 2017, DCPrime BV a firm developing dendritic cell vaccines for cancer therapy collaborated with apceth Biopharma GmbH contract manufacturer. The collaboration comprises clinical batch production and the development of an expanded-scale manufacturing process for cancer vaccines. However, a few large pharmaceutical firms prefer to maintain vaccine manufacturing in-house to avoid risks of management contingencies and deviation in safety and efficacy. This factor could have a negative impact on the global adoption of contract-based services during the forecast period.
Rising demand for expedited entry of vaccines into the market has rendered the vaccine contract manufacturing market to be highly competitive with a vast outreach across geographies. The key industrial players enjoying a dominant position in this market are Ajinomoto Althea, Inc., Albany Molecular Research, Inc., Cobra Biologics & Pharmaceutical Services, Cytovance Biologics; Catalent, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON plc., IDT Biologika GmbH, Lonza Group, Ltd., Merck KGaA, Paragon Bioservices, Inc., PRA Health Sciences and Others notable players.
Historical & Forecast Period
This study report represents an analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends, and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. A key data point that enables the estimation of the Vaccine Contract Manufacturing market is as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- A number of end users and consumption volume, price, and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Vaccine Contract Manufacturing market and their expected impact during the forecast period.
Market Segmentation
Service
- Cell line/strain development
- Upstream process development
- Downstream process development
- Analytical development
- Stability testing
- Product release
Application
- Human use
- Veterinary
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of the Vaccine Contract Manufacturing market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2031.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Vaccine Contract Manufacturing market?
- Which is the largest regional market for Vaccine Contract Manufacturing market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Vaccine Contract Manufacturing market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Vaccine Contract Manufacturing market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Vaccine Contract Manufacturing Market
2.2. Global Vaccine Contract Manufacturing Market, By Service, 2022 (US$ Million)
2.3. Global Vaccine Contract Manufacturing Market, By Application, 2022 (US$ Million)
2.4. Global Vaccine Contract Manufacturing Market, By Geography, 2022 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2022
3. Vaccine Contract Manufacturing Market: Competitive Analysis
3.1. Market Positioning of Key Vaccine Contract Manufacturing Market Vendors
3.2. Strategies Adopted by Vaccine Contract Manufacturing Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031
4. Vaccine Contract Manufacturing Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Vaccine Contract Manufacturing Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
5.3.1. Cell line/strain development
5.3.2. Upstream process development
5.3.3. Downstream process development
5.3.4. Analytical development
5.3.5. Stability testing
5.3.6. Product release
6. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
6.3.1. Human use
6.3.2. Veterinary
7. North America Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)
7.1. Market Overview
7.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
7.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
7.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
7.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
7.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
7.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
8. UK and European Union Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)
8.1. Market Overview
8.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
8.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
8.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
8.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
8.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
8.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
8.4.1.4.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
8.4.1.5. France
8.4.1.5.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
8.4.1.5.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
8.4.1.6.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
9. Asia Pacific Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)
9.1. Market Overview
9.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
9.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
9.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
9.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
9.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
9.4.1.3. India
9.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
9.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
9.4.1.4.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
9.4.1.5.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
9.4.1.6.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
10. Latin America Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)
10.1. Market Overview
10.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
10.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
10.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
10.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
10.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
10.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
11. Middle East and Africa Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)
11.1. Market Overview
11.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
11.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
11.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
11.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
11.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
11.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
12. Company Profile
12.1. Ajinomoto Althea, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Albany Molecular Research, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Cobra Biologics & Pharmaceutical Services
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Cytovance Biologics
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Catalent, Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. ICON plc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. IDT Biologika GmbH
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Lonza Group, Ltd.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Merck KGaA
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Paragon Bioservices, Inc.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. PRA Health Sciences
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Others notable players
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives
List of Figures
Figure 1 Global Vaccine Contract Manufacturing Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Vaccine Contract Manufacturing Market: Quality Assurance
Figure 5 Global Vaccine Contract Manufacturing Market, By Service, 2022
Figure 6 Global Vaccine Contract Manufacturing Market, By Application, 2022
Figure 7 Global Vaccine Contract Manufacturing Market, By Geography, 2022
Figure 8 Market Geographical Opportunity Matrix - Global Vaccine Contract Manufacturing Market, 2022
Figure 9 Market Positioning of Key Vaccine Contract Manufacturing Market Players, 2022
Figure 10 Global Vaccine Contract Manufacturing Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
Figure 11 Global Vaccine Contract Manufacturing Market, By Service, 2022 Vs 2031, %
Figure 12 Global Vaccine Contract Manufacturing Market, By Application, 2022 Vs 2031, %
Figure 13 U.S. Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 14 Canada Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 15 Rest of North America Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 16 UK Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 17 Germany Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 18 Spain Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 19 Italy Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 20 France Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 21 Rest of Europe Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 22 China Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 23 Japan Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 24 India Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 25 Australia Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 26 South Korea Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 27 Rest of Asia Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 28 Brazil Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 29 Mexico Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 30 Rest of Latin America Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 31 GCC Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 32 Africa Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
Figure 33 Rest of Middle East and Africa Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
List of Figures
Table 1 Global Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 2 Global Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 3 North America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 4 North America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 5 U.S. Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 6 U.S. Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 7 Canada Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 8 Canada Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 9 Rest of North America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 10 Rest of North America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 11 UK and European Union Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 12 UK and European Union Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 13 UK Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 14 UK Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 15 Germany Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 16 Germany Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 17 Spain Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 18 Spain Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 19 Italy Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 20 Italy Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 21 France Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 22 France Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 23 Rest of Europe Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 24 Rest of Europe Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 25 Asia Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 26 Asia Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 27 China Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 28 China Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 29 Japan Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 30 Japan Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 31 India Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 32 India Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 33 Australia Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 34 Australia Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 35 South Korea Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 36 South Korea Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 37 Latin America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 38 Latin America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 39 Brazil Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 40 Brazil Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 41 Mexico Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 42 Mexico Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 43 Rest of Latin America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 44 Rest of Latin America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 45 Middle East and Africa Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 46 Middle East and Africa Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 47 GCC Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 48 GCC Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 49 Africa Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 50 Africa Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Table 51 Rest of Middle East and Africa Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
Table 52 Rest of Middle East and Africa Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
Companies Mentioned
- Ajinomoto Althea Inc.
- Albany Molecular Research Inc.
- Cobra Biologics & Pharmaceutical Services
- Cytovance Biologics; Catalent Inc.
- FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
- ICON plc.
- IDT Biologika GmbH
- Lonza Group
- Ltd.
- Merck KGaA
- Paragon Bioservices Inc.
- PRA Health Sciences
